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Abstract
Genome-wide association studies (GWAS) have been shown to be
a powerful way of identifying novel susceptibility genes in systemic
lupus erythematosus (SLE), as demonstrated by a series of
publications in the past year. Lupus has been a late-comer to the
GWAS community, being preceded by success stories for the
GWAS approach in other autoimmune diseases, including type I
diabetes, ankylosing spondylitis, rheumatoid arthritis, Crohn’s
disease and ulcerative colitis. The paper by Suarez-Gestal and
colleagues seeks to exploit the wealth of data available from a total
of four GWAS in SLE, three in European-American populations and
one in a Swedish population. The authors describe replication of
ten lupus susceptibility alleles in a Spanish SLE case-control study.
Suarez-Gestal and colleagues [1] selected single variants
from either systemic lupus erythematosus (SLE) genome-
wide association studies (GWAS) or large candidate-gene-
based association studies. Three of the markers tested were
identified in all three European-American GWAS. Four more
were discovered in a single GWAS; either the International
Consortium for Systemic Lupus Erythematosus Genetics
(SLEGEN) studies [2-4] or a Swedish study [5]. The remain-
ing three variants were found in a smaller candidate-gene or
regional association study. This study by Suarez-Gestal and
colleagues represents an important step forward in SLE
genetics because it uses a Spanish population to confirm
most of the predominantly European-American associations.
It appears that the SLE genetics community have learned
valuable lessons in GWAS design from the experiences of
other complex trait geneticists where replication studies were
less consistent and yielded a multiplicity of false positives and
negatives [6]. The lack of replication in other complex
diseases may reflect a number of flaws in their GWAS
design, including inadequate sample sizes, population stratifi-
cation, poor quality control of genotyping and substandard
matching of cases and controls [7]. Independent replication
is an important step in endorsing novel susceptibility genes
because it both confirms the validity of the GWAS design as
well as verifies the contribution of a given locus to disease
pathogenesis.
Suarez-Gestal and colleagues confirmed nine of the ten
previous associations. This paper represents a major step
forward for SLE because each of the loci containing these
single nucleotide polymorphisms (SNPs) can now be
examined in more detail to determine biological mechanisms
and to gain a greater understanding of their roles in the
pathogenic process of SLE. The remaining variant, in the
coding region of LY9, a gene that forms part of the signalling-
lymphocyte-activation molecule (SLAM) locus [8], did not
replicate. Possible reasons for this are population-specific
differences in allele frequency or haplotype structure between
the northern and southern European populations [9] or,
alternatively, too little power to detect it. The advent of
HAPMAP phase 3, with increased numbers for the original
four populations, increases the reliability for the tag-SNP
selection as well as adds an additional seven population
groups for better correlation between the population used for
tag-SNP selection and a wider number of study cohorts. This
would minimise the effect of population-specific differences
in haplotype structure by allowing for the presence of multiple
risk haplotypes carrying a particular risk allele(s) while
minimising the type I or II errors due to population-specific
differences in allele frequency for single variants.
The ideal replication study design would be to perform a
meta-analysis of the existing SLE GWAS data and then
select the variants showing the strongest association.
Suarez-Gestal and colleagues chose four variants, each
identified by a single GWAS, since there is no publically
available meta-analysis for all the current GWAS. The lack of
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reproducibility between GWAS may reflect an overall lack of
power for each individual study, since each published
GWAS was of intermediate size (1,100 cases or less) and
there was some sample duplication between them. The other
factor that may contribute to the diversity of strongly
associated SNPs between different studies is the
heterogeneity of the disease phenotype, which may reflect
the underlying genetic heterogeneity. Consequently, there is
clear need for a much larger additional GWAS, in both
Europeans and non-Europeans, with clearly defined clinical
criteria and at a much greater density of markers. This scale
of experiment, which is proving successful for other complex
diseases, would offset the loss of power associated with the
heterogeneity of lupus.
In complex autoimmune diseases such as lupus, a large
number of variants are expected to make a small contribution
to the overall genetic risk. Furthermore, there may be multiple
susceptibility alleles within a given gene, so that the global
risk for a given locus will be a combination of the individual
risks for each susceptibility allele in that gene. Further
complexity arises because not only do particular individuals
carry different combinations of risk alleles, but the genotyping
chips do not carry every susceptibility allele for a given locus.
Interpretation of whether a particular locus is associated with
disease may, therefore, depend on the linkage disequilibrium
between the genotyped SNP and the functional allele(s).
Patterns of linkage disequilibrium between associated SNPs
in different studies will have to be taken into consideration
before either claiming replication or the lack of it.
The replication of the variants in the paper by Suarez-Gestal
and colleagues therefore represents the tip of the iceberg
because it has confirmed the association of a number of
common risk alleles of moderate disease risk identified from
intermediate-sized GWAS. To test rarer mutations (minor
allele frequency <0.1%), such as those that will be generated
by the 1000 Genomes Project, it may be necessary to both
design custom chips, since even the latest generation of
GWAS chips [10] will not carry rarer mutations, and also
genotype them in very large populations. However, we
anticipate that there will be a larger number of genes with a
smaller effect size (odds ratio 1.1 to 1.2), so that we will need
an increased number of samples in the study cohort to gain
sufficient power to find a significant association. Hence,
GWAS funded by the Wellcome Trust Case Control
Consortium include studies in the range of 5,000 to 10,000
samples; a study of this size is needed in SLE. These larger
population sizes will give sufficient power for the analysis of
sub-phenotypes. Nevertheless, the data presented by Suarez-
Gestal and colleagues provide a core series of independently
validated loci that, together with additional targets generated
by larger GWAS, can be used to piece together the key
pathways involved in lupus pathogenesis, with each pathway
constructed of a number of interacting proteins making an
individual contribution to disease susceptibility.
Competing interests
The author declares that they have no competing interests.
References
1. Suarez-Gestal M, Calaza M, Pullmann R, Ros JO, Sebastiani GD,
Ruzickova S, Santos MJ, Papasteriades C, Marchini M, Skopouli
FN, Saurez A, Blanco FJ, D’Alfonso S, Bijl M, Carreira P, Migliaresi
S, Gonzalez A; for the European Consortium of SLE DNA Collec-
tions: Replication of recently identified systemic lupus erythe-
matosus genetic factors: a case–control study. Arthritis Res
Ther 2009, 11:R69.
2. Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams
AH, Divers JD, Wang W, Frank SG, Namjou B, Gabriel SB, Lee
AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovet-
zki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA,
Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ,
Wakeland EK, Bruner GR, et al.:  Genome-wide association
scan in women with systemic lupus erythematosus identifies
susceptibility variants in ITGAM, PXK, KIAA1542 and other
loci. Nat Genet 2008, 40:152-154.
3. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier
S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy
R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I,
Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin
MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK,
Behrens TW: Association of systemic lupus erythematosus
with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358:
956-961.
4. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon
JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM,
Behrens TW, Wither J, Rioux JD, Fortin PR, Cunninghame
Graham DS, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL,
Gaffney PM: A genome-wide association scan identifies
tumour necrosis factor alpha inducible protein 3
(TNFAIP3/A20) as a susceptibility locus for systemic lupus
erythematosus. Nat Genet 2008, 40:1059-1061.
5. Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV,
Sanchez E, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A,
Truedsson L, Pons-Estel BA, Witte T, D’Alfonso S, Barizzone N,
Danieli MG, Gutierrez C, Suarez A, Junker P, Laustrup H, Gonza-
lez-Escribano MF, Martin J, Abderrahim H, Alarcon-Riquelme ME:
Functional variants in the B-cell gene BANK1 are associated
with systemic lupus erythematosus. Nat Genet 2008, 40:211-
216.
6. Ioannidis JPA: Non-replication and inconsistency in the
genome-wide association setting. Hum Hered 2007, 64:203-
213.
7. Neale BM, Purcell S: The positives, protocols and perils of
genome-wide association. Am J Med Genet 2008, 147B:1288-
1294.
8. Cunninghame Graham DS, Vyse TJ, Fortin PR, Montpetit A, Cai Y-
C, Lim S, McKenzie T, Farwell L, Rhodes B, Chad L, CaNIOS
GenES Investigators, Hudson TJ, Terhorst C, Sharpe AH, Green-
wood CMT, Wither J, Rioux JD: Association of LY9 in UK and
Canadian SLE Families. Genes Immun 2008, 9:1-10.
9. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA,
Reich D. Principal components analysis corrects for stratifica-
tion in genome-wide association studies. Nat Genet 2006, 38:
904-909.
10. Li M, Li C, Guan W: Evaluation of coverage variation of SNP
chips for genome-wide association studies. Eur J Hum Genet
2008, 16:635-643.